Reagan, Regulation, and the FDA
The US Food and Drug Administration's Response to HIV/Aids, 1980-90
Bibliographic Data
| ID | 7465170 |
|---|---|
| Authors | Lucas Richert (0000-0002-5593-4383, American Institute for Economic Research, corresponding author) |
| Year | 2009 |
| Volume | 44 |
| Issue | 3 |
| Pages | 467-488 |
| Publication date | 2009-12-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of History (JOURNAL) |
| Journal identifiers | ISSN: 0008-4107 • E-ISSN: 2292-8502 |
| Publisher | University of Toronto Press Inc. (UTPress) (PUBLISHER) |
| DOI | 10.3138/cjh.44.3.467 |
| OpenAlex | W256488181 |
| Language | EN |
| Citations received | 4 |
The beginning of the AIDS epidemic in the 1980s placed tremendous strain on the Food and Drug Administration, regulator of one quarter of the domestic US economy and protector of the nation's drug supply. Much has already been written on the AIDS epidemic, and this body of literature continues to expand, but careful consideration of this subject matter is of crucial significance to understanding the interaction between regulatory agencies, the executive branch, industry, and the public. Periodically, the FDA has gone through phases in which various priorities dominated. At one point or another it has distinguished itself as a regulatory agency, law enforcement agency, and science agency, depending on the political party in power, the ideology of the FDA Commissioner, and the influence of external stakeholders. The AIDS epidemic, which gave rise to a new and robust coalition of AIDS activists, reformers, and libertarians, tested the agency's institutional identity. To some commentators, the FDA’s management of the AIDS crisis was a serious blunder, akin to the Reagan administration’s failure. This paper contends, however, that despite the absence of presidential leadership, the FDA succeeded in rising to the challenge of the AIDS epidemic in the 1980s by refashioning its existing regulatory rules, reaching out to the AIDS movement and the pharmaceutical industry, and maintaining its strong commitment to consumer protection
Administration (probate law · Agency (philosophy · Business · Economics · Enforcement · Environmental health · Food and drug administration · Ideology · Law and economics · Political science · Politics · Presidential system · Regulatory state · Sociology · American History and Culture · HIV, Drug Use, Sexual Risk · Law · Medicine · Pharmaceutical industry and healthcare · Public Administration
Caring infrastructures for sexual health and the implications of antibiotic-resistant STIs
How Do Pandemic Policies and Communication Shape Intergroup Outcomes? Initial Findings From the Covid-19 Pandemic and Open Questions for Research and Policy
Redesigning the Political Science Curriculum to Incorporate LGBTQ+ Issues
Second Time Overlooked in Crisis
| Unique citing works | 4 |
|---|---|
| Citations per year | 1 |
| Citation span | 2022 - 2026 (5) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 4 |